Bio4Dreams has become a shareholder in the startup newMoA Therapeutics (newMoA^Tx), which has also embarked on a dedicated incubation process.

newMoA^Tx and target repurposing

Founded in Milan in 2023 under the initiative of Bio4Dreams and its network partners, newMoA^Tx aims to act as an intermediary and facilitator in the drug discovery process. Specifically, its goal is to promote target repurposing, that is, re-proposing known molecular targets to develop new drugs for diseases still lacking treatments.

Thanks to a solid network of strategic partnerships, such as those with Bio4Dreams and its ecosystem, newMoA^Tx has privileged access to extensive libraries of molecular targets already known and studied for a variety of diseases, and to cutting-edge platforms that utilize artificial intelligence systems and supercomputing for the identification of new pharmacological molecules.

This approach by newMoA^Tx also allows for significant reductions in the costs and time required for new drug research.

The Exscalate platform

One such platform is Exscalate, developed by Dompé, capable of evaluating more than three million molecules per second from a library of 2 trillion molecules. This capability is made possible through a strategic partnership between the pharmaceutical company and Bio4Dreams (learn more about Exscalate4Startups).

“We are proud to be part of this new reality and to access highly innovative platforms that significantly contribute to the development of new drugs for diseases that, to this day, are still without a cure.”

Beatrice Riva, CSO, newMoA Therapeutics

📗 Learn more about newMoA^Tx and other entities in our portfolio.